Up to 1.5 million people in the United States suffer from aortic stenosis, a progressive disease that affects the aortic valve of their hearts.
> Learn More
Meet Our Coordinator
For questions about TAVR —or any of the term programs provided by RWJ — contact Jennifer Joiner, MSN, RN, APN, CCRN-CSC at:
Transcatheter aortic valve replacement (TAVR) is now available to patients once deemed inoperable.
> The TAVR Procedure
Meet the experienced and highly skilled multidisciplinary team who lead RWJ's TAVR program.
> Meet the Team
Surgical AVR is the gold standard and an effective treatment of severe aortic stenosis and has been proven to provide symptomatic relief and long-term survival in adults. During the surgical valve replacement procedure, the damaged “native” heart valve is removed and replaced with a prosthetic valve. Surgical AVR is recommended for virtually all adult patients who do not have other serious medical conditions.
For patients who have been deemed inoperable for traditional open-heart surgery by a surgeon, a new procedure called transcatheter aortic valve replacement (TAVR) is now available as a treatment option. In November of 2011, the Food and Drug Administration (FDA) approved the Edwards SAPIEN Transcatheter Heart Valve for the treatment of patients with severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis. This new transcatheter procedure allows the diseased native heart valve to be replaced without open-heart surgery.
In October 2012, the FDA approved an expanded indication for the Edwards SAPIEN valve to enable the treatment of patients with severe, symptomatic native aortic valve stenosis who have been determined by a heart team that includes an experienced cardiac surgeon and cardiologist to be high risk for open-chest surgery.